Illumina to Supply Natera with Sequencing Instruments and Consumables for Non-Invasive Prenatal Testing (NIPT)

  Illumina to Supply Natera with Sequencing Instruments and Consumables for
  Non-Invasive Prenatal Testing (NIPT)

         Natera Will Continue to Use Illumina’s HiSeq® 2500 for NIPT

Business Wire

SAN DIEGO -- September 4, 2013

Illumina, Inc. (NASDAQ:ILMN) and Natera, Inc. today announced they have
entered into a three-year agreement whereby Illumina will supply Natera with
the HiSeq® 2500 sequencing system and associated consumables for performing
the non-invasive prenatal test (NIPT) Panorama™.

“We are pleased to be selected again as Natera’s next-generation sequencing
system provider, to support the growth of its Panorama™ test,” said Nick
Naclerio, Senior Vice President of Corporate and Venture Development at
Illumina. “Illumina’s goal is to enable the rapid growth of NIPT and the
broader reproductive health market with technology, products, and ultimately
FDA-approved in vitro diagnostic systems.”

Added Matthew Rabinowitz, Ph.D., Chief Executive Officer of Natera, “We are
pleased to continue working with Illumina and its next-generation sequencing
technology. This deal enables a major expansion of Natera’s laboratory
capacity to support the fast-growing demand for our Panorama™ test.”

About Illumina

Illumina ( is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

About Natera

Natera is a leading genetic testing company that has developed a proprietary
bioinformatics-based technology (NATUS) to deliver accurate and comprehensive
high-throughput testing for reproductive indications from tiny quantities of
DNA. Natera operates a CLIA-certified laboratory in San Carlos, Calif.,
providing a host of preconception and prenatal genetic testing services. Test
offerings include pre-implantation genetic diagnosis to identify chromosomal
anomalies or inherited genetic conditions in embryos generated during an IVF
cycle; products-of-conception testing following miscarriage to rapidly and
extensively analyze fetal chromosomes in order to understand the cause of the
pregnancy loss; non-invasive prenatal testing to determine paternity; carrier
screening tests to detect whether parents carry genetic variations that may
result in disease in the child; and Panorama, a safe, simple test for pregnant
women that identifies the most common chromosomal anomalies in a fetus as
early as nine weeks. Natera’s PreNATUS clinical trial for non-invasive
screening of fetal chromosomal anomalies is funded by the NIH and is being
conducted by the leaders in maternal-fetal medicine in the United States. For
more information, visit

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this


Illumina, Inc.
Rebecca Chambers, 858-255-5243
Jennifer Temple, 858-882-6822
Natera, Inc.
Ian Stone, 619-308-6541
Solomon Moshkevich, 650-249-9090
Press spacebar to pause and continue. Press esc to stop.